DK590288D0 - Kemiske forbindelser - Google Patents

Kemiske forbindelser

Info

Publication number
DK590288D0
DK590288D0 DK590288A DK590288A DK590288D0 DK 590288 D0 DK590288 D0 DK 590288D0 DK 590288 A DK590288 A DK 590288A DK 590288 A DK590288 A DK 590288A DK 590288 D0 DK590288 D0 DK 590288D0
Authority
DK
Denmark
Prior art keywords
pellet
supernatant
fraction
components
new
Prior art date
Application number
DK590288A
Other languages
English (en)
Inventor
Alan G Barbour
Sven Bergstroem
Louis Magnarelli
Original Assignee
Symbicom Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of DK590288D0 publication Critical patent/DK590288D0/da
Priority to DK590288A priority Critical patent/DK590288D0/da
Application filed by Symbicom Ab filed Critical Symbicom Ab
Priority to AT89912228T priority patent/ATE150318T1/de
Priority to CA002001328A priority patent/CA2001328C/en
Priority to AT93201345T priority patent/ATE212376T1/de
Priority to DE68927891T priority patent/DE68927891T2/de
Priority to AT00125910T priority patent/ATE432988T1/de
Priority to DE68929369T priority patent/DE68929369T2/de
Priority to EP95203128A priority patent/EP0711563B1/en
Priority to DE68929565T priority patent/DE68929565D1/de
Priority to EP00125910A priority patent/EP1092774B1/en
Priority to PCT/DK1989/000248 priority patent/WO1990004411A1/en
Priority to DE68929550T priority patent/DE68929550T2/de
Priority to EP93201345A priority patent/EP0565208B1/en
Priority to AU44953/89A priority patent/AU639667B2/en
Priority to EP89912228A priority patent/EP0445135B1/en
Priority to NO91911602A priority patent/NO911602L/no
Priority to FI911964A priority patent/FI112366B/fi
Priority to DK199100750A priority patent/DK175844B1/da
Priority to US08/137,175 priority patent/US5777095A/en
Priority to US08/079,601 priority patent/US5523089A/en
Priority to US08/262,220 priority patent/US6054296A/en
Priority to US08/264,036 priority patent/US6300101B1/en
Priority to US08/320,416 priority patent/US5582990A/en
Priority to US08/375,993 priority patent/US5688512A/en
Priority to US08/470,638 priority patent/US6509017B1/en
Priority to US08/471,019 priority patent/US6083722A/en
Priority to US08/466,393 priority patent/US6183986B1/en
Priority to US08/479,017 priority patent/US6143872A/en
Priority to US08/470,627 priority patent/US6203798B1/en
Priority to US08/588,637 priority patent/US7094391B1/en
Priority to JP9526117A priority patent/JP2000507209A/ja
Priority to IL12532397A priority patent/IL125323A0/xx
Priority to EP97904758A priority patent/EP0876156A4/en
Priority to PCT/US1997/000557 priority patent/WO1997026006A1/en
Priority to AU17470/97A priority patent/AU740048B2/en
Priority to ZA9700459A priority patent/ZA97459B/xx
Priority to NO983220A priority patent/NO983220L/no
Priority to FI981624A priority patent/FI981624A/fi
Priority to US09/973,406 priority patent/US6814970B2/en
Priority to DK200401413A priority patent/DK200401413A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1207—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK590288A 1919-10-24 1988-10-24 Kemiske forbindelser DK590288D0 (da)

Priority Applications (40)

Application Number Priority Date Filing Date Title
DK590288A DK590288D0 (da) 1988-10-24 1988-10-24 Kemiske forbindelser
EP89912228A EP0445135B1 (en) 1988-10-24 1989-10-24 Immogenically active fractions of borrelia burgdorferi
DE68929565T DE68929565D1 (de) 1988-10-24 1989-10-24 Borrelia burgdorferi OspA Polypeptid zur Immunisierung gegen Lymeborreliose
PCT/DK1989/000248 WO1990004411A1 (en) 1988-10-24 1989-10-24 Immunogenically active fractions of borrelia burgdorferi
AT93201345T ATE212376T1 (de) 1988-10-24 1989-10-24 Dns fragmente, die für borrelia burgdorferi ospa kodieren, verfahren zur herstellung von ospa polypeptiden, und diagnostische verfahren basierend auf diesen dns fragmenten
DE68927891T DE68927891T2 (de) 1988-10-24 1989-10-24 Fraktionen von BORELLA BURGDORFERI mit immunogener Wirkung
AT00125910T ATE432988T1 (de) 1988-10-24 1989-10-24 Borrelia burgdorferi ospa polypeptid zur immunisierung gegen lymeborreliose
DE68929369T DE68929369T2 (de) 1988-10-24 1989-10-24 DNS Fragmente, die für Borrelia burgdorferi OspA kodieren, Verfahren zur Herstellung von OspA Polypeptiden, und diagnostische Verfahren basierend auf diesen DNS Fragmenten
EP95203128A EP0711563B1 (en) 1988-10-24 1989-10-24 Substantially pure entire ospa protein free from other b. burgdorferi related material
AT89912228T ATE150318T1 (de) 1988-10-24 1989-10-24 Fraktionen von borella burgdorferi mit immunogener wirkung
EP00125910A EP1092774B1 (en) 1988-10-24 1989-10-24 Borrelia burgdorferi OspA polypeptide for immunization against Lyme disease
CA002001328A CA2001328C (en) 1988-10-24 1989-10-24 Borrelia antigen
DE68929550T DE68929550T2 (de) 1988-10-24 1989-10-24 Im Wesentlichen reines ganzes OspaA-Protein, frei von anderen B. burgdorferi-Materialien
EP93201345A EP0565208B1 (en) 1988-10-24 1989-10-24 DNA fragments encoding OspA of Borrelia burgdorferi, method of preparation of OspA polypeptides and diagnostic methods based upon said DNA fragments
AU44953/89A AU639667B2 (en) 1988-10-24 1989-10-24 Immunogenically active fractions of borrelia burgdorferi
DK199100750A DK175844B1 (da) 1988-10-24 1991-04-23 DNA fragment, der koder for et Borrelia burgdorferi OspA polypeptid, en vektor, en værtsmikroorganisme, en fremgangsmåde til fremstilling af OspA polypeptider samt en fremgangsmåde til diagnosticering af Borrelia burgdorferi infektion
NO91911602A NO911602L (no) 1988-10-24 1991-04-23 Immunogent aktive fraksjoner av borrelia burgdorferi.
FI911964A FI112366B (fi) 1988-10-24 1991-04-23 Menetelmä organismin Borrelia burgdorferi OspA -polypeptidin ja sitä tuottavan organismin valmistamiseksi ja menetelmässä käytettäviä välineitä
US08/137,175 US5777095A (en) 1988-10-24 1992-10-22 Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
US08/079,601 US5523089A (en) 1988-10-24 1993-06-22 Borrelia antigen
US08/262,220 US6054296A (en) 1988-10-24 1994-06-20 66 kDa antigen from Borrelia
US08/264,036 US6300101B1 (en) 1988-10-24 1994-06-22 Methods and compositions including a 13kD B. burgdorferi protein
US08/320,416 US5582990A (en) 1988-10-24 1994-10-03 DNA encoding borrelia burgdorferi OspA and a method for diagnosing borrelia burgdorferi infection
US08/375,993 US5688512A (en) 1988-10-22 1995-01-20 Borrelia antigen
US08/470,638 US6509017B1 (en) 1919-10-24 1995-06-06 66 KDA antigen from Borrelia
US08/471,019 US6083722A (en) 1988-10-24 1995-06-06 Borrelia antigen
US08/466,393 US6183986B1 (en) 1988-10-24 1995-06-06 OspA DNA and lyme disease vaccine
US08/479,017 US6143872A (en) 1988-10-24 1995-06-06 Borrelia burdorferi Osp A and B proteins and immunogenic peptides
US08/470,627 US6203798B1 (en) 1988-10-24 1995-06-06 Borrelia antigen
US08/588,637 US7094391B1 (en) 1988-10-24 1996-01-19 Compositions and methods for administering Borrelia burgdorferi antigens
AU17470/97A AU740048B2 (en) 1988-10-24 1997-01-17 Compositions and methods for administering borrelia burgdorferi antigens
JP9526117A JP2000507209A (ja) 1988-10-24 1997-01-17 ボレリア・ブルグドフェリ（Ｂｏｒｒｅｌｉａ ｂｕｒｇｄｏｒｆｅｒｉ）抗原を投与するための組成物および方法
IL12532397A IL125323A0 (en) 1988-10-24 1997-01-17 Compositions and methods for administering borrelia burgdorferi antigens
EP97904758A EP0876156A4 (en) 1988-10-24 1997-01-17 COMPOSITIONS AND METHODS FOR ADMINISTERING BORRELIA BURGDORFERI ANTIGENS
PCT/US1997/000557 WO1997026006A1 (en) 1988-10-24 1997-01-17 Compositions and methods for administering borrelia burgdorferi antigens
ZA9700459A ZA97459B (en) 1988-10-24 1997-01-20 Composition and methods for administering borrelia burgdorferi antigens.
NO983220A NO983220L (no) 1988-10-24 1998-07-13 Sammensetninger og fremgangsmåter for å administrere Borrelia Burgdorferi-antigener
FI981624A FI981624A (fi) 1988-10-24 1998-07-16 Koostumukset ja menetelmät Borrelia burgdorferi antigeenien annostelemiseksi
US09/973,406 US6814970B2 (en) 1988-10-24 2001-10-09 Methods and compositions including a 13 kD B. burgdorferi protein
DK200401413A DK200401413A (da) 1988-10-24 2004-09-17 OspA polypeptid, præparat omfattende OspA polypeptidet og anvendelse af OspA polypeptidet til fremstilling af et præparat til immunisering mod Lyme Disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK590288A DK590288D0 (da) 1988-10-24 1988-10-24 Kemiske forbindelser

Publications (1)

Publication Number Publication Date
DK590288D0 true DK590288D0 (da) 1988-10-24

Family

ID=8146053

Family Applications (3)

Application Number Title Priority Date Filing Date
DK590288A DK590288D0 (da) 1919-10-24 1988-10-24 Kemiske forbindelser
DK199100750A DK175844B1 (da) 1988-10-24 1991-04-23 DNA fragment, der koder for et Borrelia burgdorferi OspA polypeptid, en vektor, en værtsmikroorganisme, en fremgangsmåde til fremstilling af OspA polypeptider samt en fremgangsmåde til diagnosticering af Borrelia burgdorferi infektion
DK200401413A DK200401413A (da) 1988-10-24 2004-09-17 OspA polypeptid, præparat omfattende OspA polypeptidet og anvendelse af OspA polypeptidet til fremstilling af et præparat til immunisering mod Lyme Disease

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK199100750A DK175844B1 (da) 1988-10-24 1991-04-23 DNA fragment, der koder for et Borrelia burgdorferi OspA polypeptid, en vektor, en værtsmikroorganisme, en fremgangsmåde til fremstilling af OspA polypeptider samt en fremgangsmåde til diagnosticering af Borrelia burgdorferi infektion
DK200401413A DK200401413A (da) 1988-10-24 2004-09-17 OspA polypeptid, præparat omfattende OspA polypeptidet og anvendelse af OspA polypeptidet til fremstilling af et præparat til immunisering mod Lyme Disease

Country Status (10)

Country Link
US (6) US5523089A (da)
EP (4) EP0445135B1 (da)
AT (3) ATE432988T1 (da)
AU (1) AU639667B2 (da)
CA (1) CA2001328C (da)
DE (4) DE68929565D1 (da)
DK (3) DK590288D0 (da)
FI (1) FI112366B (da)
NO (1) NO911602L (da)
WO (1) WO1990004411A1 (da)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054296A (en) 1988-10-24 2000-04-25 Symbicom Ab 66 kDa antigen from Borrelia
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US6143872A (en) * 1988-10-24 2000-11-07 Symbicom Aktiebolag Borrelia burdorferi Osp A and B proteins and immunogenic peptides
US6300101B1 (en) * 1988-10-24 2001-10-09 Board Of Regents, The University Of Texas System Methods and compositions including a 13kD B. burgdorferi protein
US7094391B1 (en) * 1988-10-24 2006-08-22 The University Of Texas System Compositions and methods for administering Borrelia burgdorferi antigens
US5777095A (en) * 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
ZA907419B (en) * 1989-09-19 1991-07-31 Max Planck Gesellschaft Vaccine against lyme disease
DE4015911A1 (de) * 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit
US5470712A (en) * 1990-03-05 1995-11-28 Us Health Antigenic proteins of Borrelia burgdorferi
SG47447A1 (en) * 1990-06-15 1998-04-17 Univ Yale Compositions and methods for the prevention and diagnosis of lyme disease
EP1016416A3 (en) * 1990-07-06 2002-10-23 Wyeth Vaccine against lyme disease and a challenge model for evaluating vaccine efficacy
CA2057536C (en) * 1990-12-21 1999-10-26 John J. Dunn Cloning and expression of borrelia lipoproteins
US5436000A (en) * 1991-01-11 1995-07-25 University Of Texas System Flagella-less borrelia
AU2247192A (en) * 1991-06-13 1993-01-12 Pacific Biotech, Inc. Assay for the detection of specific ligands
US5324630A (en) * 1991-06-28 1994-06-28 The Regents Of The University Of California Methods and compositions for diagnosing lyme disease
US6221363B1 (en) * 1991-07-11 2001-04-24 Baxter Aktiengesellschaft Vaccine for the prevention of lyme disease
DE69229476T2 (de) * 1991-08-15 2000-03-16 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Ospa proteine von borrelia burgdorferi untergruppen, dafür kodierende gene sowie impfstoffe
US6676942B1 (en) 1991-08-15 2004-01-13 Smithkline Beecham Biologicals (S.A.) Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
PT100980B (pt) * 1991-10-18 1999-07-30 Connaught Lab Proteinas recombinantes de borrelia, seu processo de producao, vacina contra infeccao por borrelia e agente de imunodiagnostico para a sua deteccao
ATE234365T1 (de) * 1991-10-22 2003-03-15 Symbicom Ab Verbesserungen der diagnose und der prophylaxe von borrelia burgdorferi
US5618533A (en) * 1992-02-11 1997-04-08 Yale University Flagellin-based polypeptides for the diagnosis of lyme disease
US5308753A (en) * 1992-02-20 1994-05-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for purifying and detecting IGM antibodies
US6303129B1 (en) * 1992-07-28 2001-10-16 Rx Technologies Production of borrelia burgdorferi vaccine, product produced thereby and method of use
BE1006728A3 (fr) * 1993-02-19 1994-11-29 Wallone Region Sondes d'acides nucleiques specifiques au spirochete borrelia burgdorferi.
US6716591B1 (en) 1993-07-30 2004-04-06 Yale University B. burgdorferi polypeptides
US5656451A (en) * 1993-07-30 1997-08-12 Yale University OspE, OspF, and S1 polypeptides in borrelia burgdorferi
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
ES2265643T3 (es) * 1994-04-11 2007-02-16 Wyeth Holdings Corporation Bacteria de borrelia burgdorferi.
US6087097A (en) * 1994-05-12 2000-07-11 Mayo Foundation For Medical Education And Research PCR detection of Borrelia burgdorferi
US6312907B1 (en) 1995-04-24 2001-11-06 The Texas A & M University System DbpA compositions and methods of use
US6214355B1 (en) 1995-04-24 2001-04-10 Texas A & M University System DbpA compositions
US6248517B1 (en) 1995-04-24 2001-06-19 The Texas A & M University System Decorin binding protein compositions and methods of use
US5853987A (en) 1995-04-24 1998-12-29 The Texas A & M University System Decorin binding protein compositions and methods of use
EP0832220A1 (en) * 1995-06-07 1998-04-01 Amgen Inc. Ob protein compositions and method
ZA964896B (en) 1995-06-07 1997-01-08 Connaught Lab Expression of lipoproteins
US6251405B1 (en) * 1995-06-07 2001-06-26 Connaught Laboratories, Inc. Immunological combination compositions and methods
US6045804A (en) * 1996-03-07 2000-04-04 Mayo Foundation For Medical Educational Research Method for detecting B. burgdorferi infection
EP0915977A1 (en) * 1996-05-08 1999-05-19 Yale University B. burgdorferi polypeptides expressed in vivo
US5846946A (en) * 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
EP0979101B1 (en) 1996-07-03 2010-10-27 Merial, Inc. Recombinant canine adenovirus 2 (cav2) containing exogenous dna
DE19632862B4 (de) * 1996-08-14 2006-08-03 Mikrogen Molekularbiologische Entwicklungs-Gmbh Immunologisch aktive Proteine von Borrelia burgdorferi, dafür kodierende Nukleinsäuren sowie deren Verwendung in Testkits und als Impfstoffe
US6368603B1 (en) 1997-03-05 2002-04-09 Merial Limited Lyme combination compositions and uses
WO1998058943A1 (en) * 1997-06-20 1998-12-30 Human Genome Sciences, Inc. Borrelia burgdorferi polynucleotides and sequences
US6902893B1 (en) 1997-06-20 2005-06-07 Gil H. Choi Lyme disease vaccines
AU8177298A (en) * 1997-06-30 1999-01-19 The Administrators Of The Tulane Eductional Fund Surface antigens and proteins useful in compositions for the diagnosis and prevention of lyme disease
EP1012269A2 (en) * 1997-09-10 2000-06-28 Symbicom Ab P13 antigens from borrelia
US6610838B1 (en) 1997-09-10 2003-08-26 Symbicom Aktiebolag P13 antigens from Borrelia
US6224882B1 (en) 1997-11-07 2001-05-01 Protein Science Corp. Insect cells or fractions as adjuvant for antigens
GB9811219D0 (en) * 1998-05-26 1998-07-22 Smithkline Beecham Biolog Novel process
US6475492B1 (en) 1999-04-28 2002-11-05 The Administrators Of The Tulane Educational Fund Peptides and assays for the diagnosis of lyme disease
WO2000078345A1 (en) * 1999-06-21 2000-12-28 Milkhaus Laboratory, Inc. Method for treatment of lyme disease
US6689364B2 (en) 2000-03-21 2004-02-10 Tufts University Borrelia burgdorferi polypeptides and uses thereof
WO2001092870A2 (de) * 2000-06-02 2001-12-06 Zeptosens Ag Kit und verfahren zur multianalytbestimmung
EP1311540B1 (en) * 2000-08-18 2007-12-19 Research Foundation Of State University Of New York Altered ospa of borrelia burgdorferi
US20040033623A1 (en) * 2002-08-16 2004-02-19 Igenex, Inc. Assay for detection of antigen in bodily fluid
WO2004103269A2 (en) * 2002-10-18 2004-12-02 Macrogenics, Inc. Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of the genus borrelia
AT413945B (de) * 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
EP2030979A1 (en) * 2003-04-02 2009-03-04 The Government of the United States of America as Represented by The Department of Health and Human Services Cholesterol-containing compounds and their use as immunogens against borrelia burgdorferi
US20060051060A1 (en) * 2003-07-03 2006-03-09 Henry Dorovanessian Method and system for digitally recording broadcast content
WO2006026248A1 (en) 2004-08-25 2006-03-09 Sigma-Aldrich Co. Compositions and methods employing zwitterionic detergent combinations
US20060281139A1 (en) * 2005-05-23 2006-12-14 Viramed Biotech Ag Carrier and method for the detection of anti-borrelia antibodies and test kit for use in the diagnosis of Lyme borreliosis infections
US7663212B2 (en) 2006-03-21 2010-02-16 Infineon Technologies Ag Electronic component having exposed surfaces
US7541681B2 (en) * 2006-05-04 2009-06-02 Infineon Technologies Ag Interconnection structure, electronic component and method of manufacturing the same
BRPI0719360B1 (pt) 2006-11-03 2016-09-06 Intervet Int Bv vacina da doença de lyme canina, e, uso de organismos de uma genoespécie de borrelia
EP2361930A3 (en) 2007-03-26 2011-10-26 Dako Denmark A/S Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
EP3023436A1 (en) 2007-07-03 2016-05-25 Dako Denmark A/S Improved methods for generation, labeling and use of mhc multimers
WO2009039854A2 (en) 2007-09-27 2009-04-02 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
US20110117131A1 (en) * 2008-04-09 2011-05-19 Ning Huang Production of OspA for Lyme Disease Control
EP2711021B1 (en) 2008-05-02 2016-03-09 BliNK Therapeutics Limited Products and methods for stimulating an immune response
US10722562B2 (en) 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
EA025280B1 (ru) 2010-03-09 2016-12-30 Амир Максютов Полиэпитопные конструкции и способы их получения и применения
KR20180082633A (ko) 2010-05-14 2018-07-18 박스알타 인코퍼레이티드 Ｏｓｐａ 키메라 및 백신에서 그의 용도
US9109007B2 (en) 2010-08-18 2015-08-18 Purdue Pharma L.P. MHC-I restricted epitopes containing non-natural amino acid residues
CN103229055A (zh) 2010-09-27 2013-07-31 康奈尔大学 莱姆病的诊断方法
WO2012047970A1 (en) * 2010-10-05 2012-04-12 Board Of Trustees Of Michigan State University Regulatory factors controlling oil biosynthesis in microalgae and their use
CN104640563A (zh) 2012-07-27 2015-05-20 巴克斯特国际公司 包含嵌合的ospa分子的组合物及其使用方法
US10669567B2 (en) 2015-02-17 2020-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High sensitivity method for early Lyme disease detection
EP3442587B1 (en) 2016-04-14 2021-08-18 Boehringer Ingelheim Animal Health USA Inc. Multi-dose compositions containing an antimicrobial polyamide or octenidine preservative
WO2018227109A1 (en) 2017-06-08 2018-12-13 Colorado State University Research Foundation Differentiation of lyme disease and southern tick-associated rash illness
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
WO2023240109A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Multispecific molecules for modulating t-cell activity, and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) * 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4981685A (en) * 1986-03-07 1991-01-01 Utah State University Foundation Bacterial extract vaccines for veterinary application
US4888276A (en) 1986-06-26 1989-12-19 Minnesota Mining And Manufacturing Company Method and composition for the diagnosis of Lyme disease
US4721617A (en) * 1986-08-14 1988-01-26 Regents Of The University Of Minnesota Vaccine against lyme disease
DE4015911A1 (de) 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit

Also Published As

Publication number Publication date
US6203798B1 (en) 2001-03-20
EP1092774A2 (en) 2001-04-18
EP1092774B1 (en) 2009-06-03
ATE432988T1 (de) 2009-06-15
DE68929369T2 (de) 2002-09-26
DE68927891T2 (de) 1997-10-02
FI911964A0 (fi) 1991-04-23
DK200401413A (da) 2004-09-17
DK75091A (da) 1991-06-12
ATE212376T1 (de) 2002-02-15
NO911602D0 (no) 1991-04-23
EP0445135A1 (en) 1991-09-11
DE68927891D1 (de) 1997-04-24
DK175844B1 (da) 2005-03-29
DE68929369D1 (de) 2002-03-14
US5688512A (en) 1997-11-18
EP0565208A1 (en) 1993-10-13
EP0711563B1 (en) 2007-01-17
FI112366B (fi) 2003-11-28
US5523089A (en) 1996-06-04
US6083722A (en) 2000-07-04
DK75091D0 (da) 1991-04-23
US6183986B1 (en) 2001-02-06
CA2001328A1 (en) 1991-04-24
WO1990004411A1 (en) 1990-05-03
ATE150318T1 (de) 1997-04-15
DE68929565D1 (de) 2009-07-16
US5582990A (en) 1996-12-10
NO911602L (no) 1991-06-24
DE68929550T2 (de) 2007-12-06
AU639667B2 (en) 1993-08-05
DE68929550D1 (de) 2007-03-08
AU4495389A (en) 1990-05-14
CA2001328C (en) 2005-12-13
EP0445135B1 (en) 1997-03-19
EP1092774A3 (en) 2001-04-25
EP0565208B1 (en) 2002-01-23
EP0711563A1 (en) 1996-05-15

Similar Documents

Publication Publication Date Title
DK590288D0 (da) Kemiske forbindelser
WO1998008542A3 (en) Compounds and methods for treatment and diagnosis of mycobacterial infections
ATE294864T1 (de) Äusseres membranprotein von haemophilus
EP0338767A3 (en) Novel recombinant and chimeric antibodies directed against a human adenocarcinoma antigen
HUP9800730A2 (hu) Expressziós rendszer heterológ antigének fúziós proteinként történő expresszáltatására
ES2137931T3 (es) Proteinas gdf-1 y uog-1.
OA09866A (en) Recombinant DNA coding for signal peptide; selective interacting polypeptide and membrane anchoring sequence.
ATE387458T1 (de) Fas-antigenbindender ligand
FR2700169B1 (fr) Nouveaux variants trans-dominants TAT du virus de l'immunodéficience humaine.
Clezardin et al. Isolation of thrombospondin released from thrombinstimulated human platelets by fast protein liquid chromatography on an anion-exchange mono-q column
EP0331356A3 (en) Expression of hiv binding proteins
FI970428A (fi) Soluja, joissa on CD4-houkutusreseptoreita ja vastaavia molekyylejä ja menetelmiä
Takenaka et al. Royal jelly from Apis cerana japonica and Apis mellifera
Baumstark Comparative studies on the fractionation of human and swine serum proteins by anion-exchange chromatography and gel filtration
ATE122055T1 (de) Dna- und rna-moleküle des westlichen subtyps des fsme-virus, polypeptide, die von diesen molekülen codiert werden, und deren verwendung.
PT85093A (fr) Vecteur viral et procede de preparation de adn recombinant codant pour la proteine f du virus agent causal du s.i.d.a.
ATE101199T1 (de) Rekombinante ligninase.
DK551786D0 (da) Rekombinant-dna-sekvens, der koder for aminosyresekvenser i et toksin, expressionssystem omfattende samme og vaertsceller transformeret hermed
EP0345792A3 (en) Htlv-i / hiv-1 fusion proteins
ES2059823T3 (es) Metodos y sistemas para producir antigenos de hiv.
WO1997026361A3 (en) Bacterial donor cell useful in conjugation
Petersen et al. Hydrophobic interaction chromatography used for purification of a Treponema Reiter ribonucleic acid antigen precipitating with antibodies in human syphilitic sera
WO1998031796A8 (en) Novel ifn receptor 1 binding proteins, dna encoding them, and methods of modulating cellular response to interferons
Vila et al. Action of thrombin of platelets. Characterization of total and membrane proteins. Platelet-fibrinogen interaction
SE9404066D0 (sv) Fusion proteins of immunopotentiating activity

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment